Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Abstract

These results suggest further investigation of ipilimumab in ED-SCLC.

Updates on immunotherapy in non-small cell lung cancer

“…However, no statistically significant differences were recorded. Interestingly, a subgroup analysis of this study found that the benefit of phased ipilimumab was more pronounced in patients with squamous cell lung cancer with HR for irPFS and OS of 0.55 (95% CI 0.27 --1.12) and 0.48 (95% CI 0.22 --1.03), respectively [19]. Consequently, this led to the initiation of a Phase III clinical trial evaluating the efficacy of phased ipilimumab in patients with squamous cell histology (NCT01285609) [20].…”

“…Of note, grade 3 or 4 elevations in alanine aminotransferase were noted in phased and concurrent ipilimumab groups, but none in the control group. Overall, the rates of grade 3 --4 AEs were 21, 17 and 9% for the concurrent ipilimumab, phased ipilimumab and control groups, respectively [19].…”

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario

“…The mechanisms of action, the outcomes and the toxicity profiles of these drugs are discussed here. Most of these moAbs achieved significant improvement of overall survival by the combination with standard [113] NSCLC (No-Squ) [114] Ipilimumab Anti-CTLA-4 SCLC [107] NSCLC [108] Tremelimumab Anti-CTLA-4 Melanoma…”

“…No toxic death was registered [105]. A promising field of research on ipilimumab is represented by lung cancer [106,107]. Two Phase III trials have evaluated ipilimumab in both advanced NSCLC [108] and extensive-stage SCLC [109], showing very promising results.…”

Immune Checkpoint Inhibitors in Extensive Disease Small Cell Lung Cancer

“…Phased ipilimumab, concurrent ipilimumab and control, respectively, were associated with median median PFS of 5.2, 3.9 and 5.2 months; median OS of 12.9, 9.1 and 9.9 months. Overall rates of grade 3/4 irAEs (immun-related advers events) were 17, 21 and 9% for phased ipilimumab, concurrent ipilimumab and control, respectively [14]. A phase 3 trial comparing the efficacy of ipilimumab plus etoposide/platinum versus etoposide/platinum in patients with newly diagnosed ED-SCLC (NCT01450761) is currently ongoing.…”